cinobufotalin + hechan

Cinobufotalin + hechan is presumed to be a combination therapy involving cinobufotalin and another agent, "hechan." Cinobufotalin is a bufadienolide compound extracted from the skin secretion of Bufo bufo gargarizans or B. melanotictus, commonly used in Traditional Chinese Medicine (TCM) as an injectable preparation for cancer therapy. It acts primarily as a Na+/K+-ATPase inhibitor and has demonstrated antitumor effects through modulation of multiple signaling pathways, including MAPK, PI3K-AKT, Ras, FoxO, p53, JAK-STAT pathways. These actions result in regulation of protein phosphorylation processes that affect cell apoptosis, senescence, and cell cycle progression[2][8]. Clinical studies have shown that cinobufotalin injection combined with chemotherapy improves objective response rate (ORR), disease control rate (DCR), quality of life (QOL), and pain relief in patients with advanced cancers such as non-small cell lung cancer (NSCLC) compared to chemotherapy alone[1][4][5]. The identity or pharmacological role of "hechan" could not be determined from available sources; thus the description focuses on the known properties of cinobufotalin.